CClinicalTrials.gg
CompletedNCT03288402DIB-NETUpdated Jun 20, 2024

Investigation of the Effects of Diet on the Measurement of Plasma Chromogranin in NET Patients

An interventional study of ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast in Neuroendocrine Tumors, sponsored by University Hospitals Coventry and Warwickshire NHS Trust. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-20.

Sponsored by University Hospitals Coventry and Warwickshire NHS Trust · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
346
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Measurement of plasma chromogranin A remains the most commonly used biomarkers for both screening and monitoring of patients with gastro-entero-pancreatic neuroendocrine tumours (GEP-NET), despite several limitations that include: lack of a reference CgA standard; wide variations depending on the used assay in different laboratories; and varying sensitivity ranges from 60 to 90% with low specificity \<50%, depending on the population studied.

Surprisingly, and to the best of our knowledge, only three studies with small numbers of participants have been published that have investigated possible effects of food intake on the measurement of CgA. Most have been performed in healthy controls or patients on treatment with proton pump inhibitors for chronic gastritis (up to n = 11 per group) but only one study has investigated patients with GEP-NET, where n = 6 patients with gastric NET were included.

In this study, the investigators aim to assess the time dependent effects of normally ingested diet (5-item English breakfast; or tea or coffee; or ongoing fasted state) on plasma chromogranin A measurements, using timed measurements over 180 min following an > 10 hours overnight fast, in a randomised double-crossover design. The investigators aimed to include 25 - 35 patients with a histologically confirmed diagnosis of a GEP-NET of varying primary tumour location, tumour stage, grade; and presence or absence of treatment with long acting somatostatin analogues; as well as 10 - 15 healthy controls. In an additional small subgroup of patients who are initiated on treatment with GLP-1 analogues i.e. for type 2 diabetes or obesity, the investigators aim to establish whether injection of GLP-1 analogues has any effects on plasma CgA measurements.

02

Conditions studied

  • Neuroendocrine Tumors

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

GEP-NET patients:

  • Confirmed diagnosis of NET
  • Aged 18 or over
  • Able to provide written informed consent
  • Able to commit to 3 visits within a 4 week period
  • Able to fast overnight
  • Able to adequately read/write/speak English

CONTROLS:

  • No known diagnosis of NET
  • Aged 18 or over
  • Able to provide written informed consent
  • Able to commit to 3 visits within a 4 week period
  • Able to fast overnight
  • Able to adequately read/write/speak English

Exclusion criteria

Exclusion Criteria:

  • GEP-NET patients
  • No confirmed diagnosis of a NET
  • Under the age of 18
  • Unable to provide written informed consent
  • Pregnant women
  • Any patients who are un well on the day of their routine appointment
  • Unable to fast overnight
  • Unable to adequately read/write/speak English

CONTROLS

  • Confirmed diagnosis of NET
  • Under the age of 18
  • Unable to provide written informed consent
  • Pregnant women
  • Any patients who are un well on the day
  • Unable to fast overnight
  • Unable to adequately read/write/speak English
04

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
346 participants (actual)

Study arms

  • Experimental
    ongoing fasted

    ongoing fasted following 10 h overnight fast; series blood samples CgA over 180 min

    Other: ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast

  • Experimental
    intake of caffeine containing beverages

    10 h overnight fast; intake of caffeine containing beverages; series blood samples CgA over 180 min

    Other: ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast

  • Experimental
    intake of 5 item English breakfast

    10 h overnight fast; intake of 5-item English breakfast; series blood samples CgA over 180 min

    Other: ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast

Interventions

  • Otherongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast

    effects of ongoing fasted state; or intake caffeine containing beverages; or 5-item English breakfast on plasma CgA measurements, in series blood tests every 30 min over 180 min

05

What researchers measure

Primary outcomes

  1. changes in plasma CgA measurements related to intake of food or caffeine containing beverages, as compared to ongoing fasted state

    plasma CgA 0, 30, 60, 90, 120, 150 and 180 min

    Time frame: up to 180 min

06

Study locations

1 site
  • The ARDEN NET Centre, ENETS Centre of Excellence
    Coventry, CV2 2DX, United Kingdom
07

References and documents

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03288402
Lead sponsor
University Hospitals Coventry and Warwickshire NHS Trust
Responsible party
Sponsor
First posted
Sep 20, 2017
Start date
Feb 1, 2017
Primary completion
Aug 10, 2021
Completion
Feb 10, 2022
Last update
Jun 20, 2024

Study contacts

Martin O Weickert, Professor
study chair · The ARDEN NET Centre, ENETS CoE
Megan Symington, Dr
principal investigator · The ARDEN NET Centre, ENETS CoE
Helen Robbins, Dr
principal investigator · The ARDEN NET Centre, ENETS CoE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion